An observational study in HIV-Associated Malignant Neoplasm, HIV Infections and Cancer, sponsored by AIDS Malignancy Consortium. Completed at 16 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by AIDS Malignancy Consortium · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in HIV Infections by AIDS Malignancy Consortium — 3 open to participants now, 4 under way, none of them phase 3. HIV Infections · AIDS Malignancy Consortium.
Among the 29 studies in HIV Infections by AIDS Malignancy Consortium, this one has the largest enrollment of the 13 observational ones that give a count, is one of 3 that started in 2023, is one of 13 observational ones, and was the 27th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →3 of the 29 studies in HIV Infections by AIDS Malignancy Consortium are open now, in 1 country. Recruiting first, the newest first:
AIDS Malignancy Consortium · Sites in United States
Ages 18+
AIDS Malignancy Consortium · Sites in United States
Ages 18+
AIDS Malignancy Consortium · Sites in United States
Ages 45–80
By country, each count listing its studies:
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 4
First in 2008; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 460 is above the median of 200 across 781 observational studies indexed under HIV Infections.
Median enrollment 66 across the 16 interventional studies, 82 across the 13 observational. Of the 21 that completed or were terminated, 13 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
AIDS Malignancy Consortium is the lead sponsor of 61 studies on the registry; 9 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.
1 of the studies in HIV Infections by AIDS Malignancy Consortium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04949464AIDS Malignancy ConsortiumImpact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in HIV Infections by AIDS Malignancy Consortium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being done to understand how many people with HIV (PWH) present for cancer care across the AIDS Malignancy Consortium in the United States and if there are reasons that some PWH choose to participate, or not in cancer clinical trials. Optional quality of life surveys will be used to learn more about how HIV and cancer and HIV and cancer treatment affect people.
Primary Objective: To estimate the number of cancers in people with HIV (PWH) who present for care at domestic AMC sites
Secondary Objectives: To characterize participants that are eligible but not enrolled onto AMC clinical trials to understand site-specific and trial-specific accrual barriers
Exploratory Objectives: 1. To standardize and expand the quantity and quality of sociodemographic and cancer diagnostic and treatment characteristics collected for PWH receiving care at domestic AMC sites. 2. To describe cancer patient health-related QOL for PWH at domestic AMC sites using validated tools: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30] and Supportive Care Needs Survey Short Form 34 [SCNS-SF34]
Outline: Participants identified via screening of electronic medical records or institutional databases. All eligible participants attend one visit for the collection of broad demographic and clinical data. Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit. Data collection at study visits will occur via survey procedures and/or medical record review.
Participants with a dual diagnosis of both cancer (current or diagnosed within 5 years) and underlying HIV infection, who present for care at AMC domestic sites.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
positive. Documentation of HIV-1 infection by means of any one of the following:
Note: The term "licensed" refers to a kit that has been certified or licensed by an oversight body within the participating country and validated internally (e.g., U.S. FDA).
WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment. A reactive initial rapid test should be confirmed by either another type of rapid assay, or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), a Western blot, or a plasma HIV-1 RNA viral load.
Patient was diagnosed with or treated for cancer within the last 5 years. Participants will qualify under one of three categories:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Considering or currently receiving cancer treatment
Other: Non-Interventional · Other: Non-Interventional Follow-up
This includes cases for which there are no current definitive therapy options for cure (i.e., inoperable) but may be considered for non-standard / non-curative therapies.
Other: Non-Interventional · Other: Non-Interventional Follow-up
Prior diagnosis (within 5 years), in remission - Not currently on cancer treatment other than ART or maintenance therapy.
Other: Non-Interventional
Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.
Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
Number of Cancers in People With HIV (PWH) Who Present for Care at Domestic AMC Sites
For each cancer group listed below, the number of new and existing cases per month will be estimated. The distribution of cancer types will be computed as percentages and compared to the cancer type distribution in the HIV/AIDS Cancer Match (HACM) Study: 1. Solid organ tumors associated with human papillomavirus (HPV) infection 2. Solid organ tumors unrelated to HPV 3. Kaposi sarcoma 4. Hematologic malignancies
Time frame: Enrollment
Percentage of Participants Eligible for AMC Trials Who Are Successfully Enrolled
This will be calculated by the number of participants enrolled who meet site-based AMC trial eligibility compared to the number of eligible participants at each site who meet site-based AMC trial eligibility.
Time frame: Baseline
Describe the Cancer Diagnostics of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.
The distribution of participant cancer diagnosis variable will be summarized.
Time frame: Baseline
Describe the Gender Distribution of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.
The distribution of participant gender variable will be summarized.
Time frame: Baseline
Describe the Age Distribution of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.
The distribution of participant characteristics will be summarized. Continuous variables \[e.g. age, height, weight\] will be summarized as mean (std) if they are normally distributed, otherwise they will be summarized as median (IQR). Categorical variables \[e.g. tobacco use, ART medications, comorbidities\] will be summarized as frequency (%).
Time frame: Baseline and 12 weeks
Describe the Treatment Characteristics of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.
The distribution of participant cancer treatment at enrollment will be summarized.
Time frame: Baseline
Planned Cancer Therapy for Cancer Patients With HIV Initiating Therapy or Currently Under Treatment
The frequency of planned cancer treatment regimens (at baseline) successfully initiated will be summarized.
Time frame: 12 weeks
Describe the Health-related QOL of Cancer Patients With HIV at Domestic AMC Sites Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30]
EORTC QLQ-C30 subscale and overall scores will be used to describe participant symptom and health-related quality of life burden. Baseline EORTC QLQ-C30 scores will be compared according to cancer group. The EORTC QLQ-C30 is a 30-item core cancer specific questionnaire measuring QOL in cancer patients. It incorporates five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and single items assessing additional symptoms and perceived financial impact of the disease. Most questions use a 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions use a 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=higher response level.
Time frame: Baseline
Describe the Supportive Care Needs of Cancer Patients With HIV at Domestic AMC Sites Using Supportive Care Needs Survey Short Form 34 [SCNS-SF34]
Supportive Care Needs Survey Short Form 34 \[SCNS-SF34\] scores will be used to categorize participants based on the degree to which their needs are met. Baseline SCNS-SF34 scores will be compared according to cancer group. The SCNS-SF34 is a 34-item questionnaire measuring the supportive care need and level of need for people diagnosed with cancer in the last month. It incorporates the underlying domains: physical and daily living, psychological, sexuality and health system, information and patient support. All the questions use 5-point scale (1 'Not applicable' to 5 'High need); with a higher score indicating a higher level of need.
Time frame: Baseline
Change of Quality of Life at 12 Weeks From Baseline for Cancer Patients With HIV Initiating Therapy or Currently Under Treatment Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30]
EORTC QLQ-C30 will be summarized, both overall and at the \~12-week follow-up, according to participant characteristics and cancer groups. Overall change in QOL will be compared with paired tests and change according to groups will be compared using t-tests, ANOVA, or nonparametric tests. The EORTC QLQ-C30 is a 30-item core cancer specific questionnaire measuring QOL in cancer patients. It incorporates five functional scales (physical, role,cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and a number of single items assessing additional symptoms and perceived financial impact of the disease. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=higher response level.
Time frame: Baseline and 12 weeks
Change of Needs From Baseline for Cancer Patients With HIV Initiating Therapy or Currently Under Treatment Using Supportive Care Needs Short Survey Form 34 [SCNS-SF34]
Supportive Care Needs Short Survey Form 34 \[SCNS-SF34\] scores will be summarized, both overall and at the \~12-week follow-up, according to participant characteristics and cancer groups. Overall change in scores will be compared with paired tests and change according to groups will be compared using t-tests, ANOVA, or nonparametric tests. The SCNS-SF34 is a 34-item questionnaire measuring the supportive care need and level of need for people diagnosed with cancer in the last month. It incorporates the underlying domains: physical and daily living, psychological, sexuality and health system, information and patient support. All the questions use 5-point scale (1 'Not applicable' to 5 'High need). Scores are averaged, and transformed to 0-100 scale;, with a higher score indicating a higher level of need.
Time frame: Baseline and 12 weeks
| Milestone | New, Primary or Recurrent Disease | Metastic or Locally Advanced Cancer | Prior Cancer |
|---|---|---|---|
| Started | 268 | 33 | 159 |
| Completed | 268 | 33 | 159 |
| Not completed | 0 | 0 | 0 |
For each cancer group listed below, the number of new and existing cases per month will be estimated. The distribution of cancer types will be computed as percentages and compared to the cancer type distribution in the HIV/AIDS Cancer Match (HACM) Study: 1. Solid organ tumors associated with human papillomavirus (HPV) infection 2. Solid organ tumors unrelated to HPV 3. Kaposi sarcoma 4. Hematologic malignancies
| Participants | New, Primary or Recurrent Disease | Metastic or Locally Advanced Cancer | Prior Cancer |
|---|---|---|---|
| Hematologic malignancies | 43 | 0 | 35 |
| Kaposi sarcoma | 87 | 6 | 15 |
| Solid organ tumor associated with HPV infection | 30 | 10 | 32 |
| Solid organ tumors unrelated HPV | 55 | 13 | 55 |
| Other | 52 | 4 | 22 |
| Unknown | 1 | 0 | 0 |
This will be calculated by the number of participants enrolled who meet site-based AMC trial eligibility compared to the number of eligible participants at each site who meet site-based AMC trial eligibility.
| percentage of enrolled in AMC studies | New, Primary or Recurrent Disease | Metastic or Locally Advanced Cancer | Prior Cancer |
|---|---|---|---|
| Percentage of Participants Eligible for AMC Trials Who Are Successfully Enrolled | 40 | 50 | 50 |
The distribution of participant cancer diagnosis variable will be summarized.
| Participants | New, Primary or Recurrent Disease | Metastic or Locally Advanced Cancer | Prior Cancer |
|---|---|---|---|
| Hematologic malignancy | 86 | 1 | 53 |
| Kaposi Sarcoma | 85 | 4 | 20 |
| Solid Tumors associated with HPV infection | 30 | 7 | 36 |
| Solid Tumors unrelated to HPV | 60 | 20 | 48 |
| Unknown | 7 | 1 | 2 |
The distribution of participant gender variable will be summarized.
| Participants | New, Primary or Recurrent Disease | Metastic or Locally Advanced Cancer | Prior Cancer |
|---|---|---|---|
| Female | 37 | 3 | 31 |
| Male | 221 | 30 | 125 |
| Transgender | 4 | 0 | 2 |
| Refused | 3 | 0 | 0 |
| Unknown | 3 | 0 | 1 |
The distribution of participant characteristics will be summarized. Continuous variables \[e.g. age, height, weight\] will be summarized as mean (std) if they are normally distributed, otherwise they will be summarized as median (IQR). Categorical variables \[e.g. tobacco use, ART medications, comorbidities\] will be summarized as frequency (%).
| Participants | New, Primary or Recurrent Disease | Metastic or Locally Advanced Cancer | Prior Cancer |
|---|---|---|---|
| Age: <50 years | 104 | 9 | 35 |
| Age:50-59 years | 63 | 9 | 46 |
| Age:60-69 years | 77 | 13 | 64 |
| Age: >=70 years | 24 | 2 | 14 |
The distribution of participant cancer treatment at enrollment will be summarized.
| Participants | New, Primary or Recurrent Disease | Metastic or Locally Advanced Cancer | Prior Cancer |
|---|---|---|---|
| No Cancer treatment at enrollment | 102 | 10 | 1 |
| Cancer Treatment at enrollment (Chemotherapy) | 131 | 17 | 0 |
| Cancer Treatment at enrollment (Non-chemotherapy) | 33 | 5 | 0 |
| Unknown | 2 | 1 | 158 |
The frequency of planned cancer treatment regimens (at baseline) successfully initiated will be summarized.
| Participants | New, Primary or Recurrent Disease | Metastic or Locally Advanced Cancer | Prior Cancer |
|---|---|---|---|
| Planned additional therapy | 95 | 14 | 0 |
| No additional therapy | 171 | 18 | 1 |
| Unknown/missing | 2 | 1 | 158 |
EORTC QLQ-C30 subscale and overall scores will be used to describe participant symptom and health-related quality of life burden. Baseline EORTC QLQ-C30 scores will be compared according to cancer group. The EORTC QLQ-C30 is a 30-item core cancer specific questionnaire measuring QOL in cancer patients. It incorporates five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and single items assessing additional symptoms and perceived financial impact of the disease. Most questions use a 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions use a 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=higher response level.
| score on a scale between 0 and 100 | New, Primary or Recurrent Disease | Metastic or Locally Advanced Cancer | Prior Cancer |
|---|---|---|---|
| Global Health | 75 (7.14 to 92.86) | 60.7 (7.14 to 92.86) | 71.4 (7.14 to 92.85) |
| Functional Scale | 58.3 (5 to 76.67) | 58.3 (13.3 to 76.67) | 65 (21.67 to 76.67) |
| Symptom Scale | 44.2 (23.1 to 92.3) | 43.3 (26.9 to 90.38) | 34.6 (23.1 to 86.53) |
Supportive Care Needs Survey Short Form 34 \[SCNS-SF34\] scores will be used to categorize participants based on the degree to which their needs are met. Baseline SCNS-SF34 scores will be compared according to cancer group. The SCNS-SF34 is a 34-item questionnaire measuring the supportive care need and level of need for people diagnosed with cancer in the last month. It incorporates the underlying domains: physical and daily living, psychological, sexuality and health system, information and patient support. All the questions use 5-point scale (1 'Not applicable' to 5 'High need); with a higher score indicating a higher level of need.
| score on a scale between 0 and 100 | New, Primary or Recurrent Disease | Metastic or Locally Advanced Cancer | Prior Cancer |
|---|---|---|---|
| Physical and daily living needs | 51.6 ± 22.2 | 55.7 ± 25.7 | 45.3 ± 23.4 |
| Psychological needs | 50.4 ± 21.5 | 54.9 ± 24.3 | 43 ± 18.7 |
| Sexual needs | 40.8 ± 22.4 | 41.7 ± 17.7 | 35.5 ± 19.6 |
| Care and support needs | 39.7 ± 17.4 | 41.8 ± 17.1 | 36.6 ± 15.5 |
| Health system and information needs | 43.5 ± 18.6 | 44.9 ± 15.6 | 38.4 ± 15.2 |
EORTC QLQ-C30 will be summarized, both overall and at the \~12-week follow-up, according to participant characteristics and cancer groups. Overall change in QOL will be compared with paired tests and change according to groups will be compared using t-tests, ANOVA, or nonparametric tests. The EORTC QLQ-C30 is a 30-item core cancer specific questionnaire measuring QOL in cancer patients. It incorporates five functional scales (physical, role,cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and a number of single items assessing additional symptoms and perceived financial impact of the disease. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=higher response level.
| score on a scale between -100 and 100 | New, Primary or Recurrent Disease | Metastic or Locally Advanced Cancer | Prior Cancer |
|---|---|---|---|
| Global Health Scale | 0 (-57.1 to 85.7) | 0 (-42.9 to 28.6) | 0 (-14.3 to 14.3) |
| Functional Scale | 1.7 (-21.7 to 35) | -2.5 (-15 to 38.3) | 0 (-1.7 to 3.3) |
| Symptom Scale | -1.9 (-40.4 to 28.8) | 0 (-26.9 to 13.5) | 0 (0 to 3.8) |
Supportive Care Needs Short Survey Form 34 \[SCNS-SF34\] scores will be summarized, both overall and at the \~12-week follow-up, according to participant characteristics and cancer groups. Overall change in scores will be compared with paired tests and change according to groups will be compared using t-tests, ANOVA, or nonparametric tests. The SCNS-SF34 is a 34-item questionnaire measuring the supportive care need and level of need for people diagnosed with cancer in the last month. It incorporates the underlying domains: physical and daily living, psychological, sexuality and health system, information and patient support. All the questions use 5-point scale (1 'Not applicable' to 5 'High need). Scores are averaged, and transformed to 0-100 scale;, with a higher score indicating a higher level of need.
| score on a scale between -100 and 100 | New, Primary or Recurrent Disease | Metastic or Locally Advanced Cancer | Prior Cancer |
|---|---|---|---|
| Physical and daily living needs | -1.75 ± 19.1 | 9.5 ± 20.8 | -0.8 ± 1.8 |
| Psychological needs | -3.17 ± 16.5 | 0.3 ± 29.7 | 0.3 ± 1.4 |
| Sexual needs | -3.2 ± 19.5 | -4.2 ± 15.1 | -1.1 ± 2.7 |
| Care and support needs | -2.7 ± 14.0 | 9.3 ± 19.8 | 0 ± 0 |
| Health system and information needs | -1.3 ± 17.4 | 1.8 ± 12.4 | -0.3 ± 0.7 |
Collected over This study is observational study. Adverse events are not collected.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| New, Primary or Recurrent Disease | — | — | — |
| Metastic or Locally Advanced Cancer | — | — | — |
| Prior Cancer | — | — | — |
| Age, Continuous(years) | New, Primary or Recurrent Disease | Metastic or Locally Advanced Cancer | Prior Cancer | Total |
|---|---|---|---|---|
| Median | 55 (20 to 83) | 59 (27 to 71) | 59 (23 to 83) | 57 (20 to 83) |
| Sex/Gender, Customized(Participants) | New, Primary or Recurrent Disease | Metastic or Locally Advanced Cancer | Prior Cancer | Total |
|---|---|---|---|---|
| Female | 37 | 3 | 31 | 71 |
| Male | 221 | 30 | 125 | 376 |
| Transgender | 4 | 0 | 2 | 6 |
| Not reported/Unknown | 6 | 0 | 1 | 7 |
| Ethnicity (NIH/OMB)(Participants) | New, Primary or Recurrent Disease | Metastic or Locally Advanced Cancer | Prior Cancer | Total |
|---|---|---|---|---|
| Hispanic or Latino | 62 | 4 | 45 | 111 |
| Not Hispanic or Latino | 199 | 29 | 107 | 335 |
| Unknown or Not Reported | 7 | 0 | 7 | 14 |
| Race (NIH/OMB)(Participants) | New, Primary or Recurrent Disease | Metastic or Locally Advanced Cancer | Prior Cancer | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 0 | 2 |
| Asian | 3 | 0 | 2 | 5 |
| Native Hawaiian or Other Pacific Islander | 3 | 0 | 0 | 3 |
| Black or African American | 101 | 17 | 61 | 179 |
| White | 125 | 15 | 70 | 210 |
| More than one race | 2 | 0 | 0 | 2 |
| Unknown or Not Reported | 32 | 1 | 26 | 59 |
| Education(Participants) | New, Primary or Recurrent Disease | Metastic or Locally Advanced Cancer | Prior Cancer | Total |
|---|---|---|---|---|
| Never attended school | 2 | 0 | 1 | 3 |
| High school graduate or below | 57 | 7 | 48 | 112 |
| College degree or equivalent | 77 | 11 | 47 | 135 |
| Unknown/not reported | 132 | 15 | 63 | 210 |
| Smoking history(Participants) | New, Primary or Recurrent Disease | Metastic or Locally Advanced Cancer | Prior Cancer | Total |
|---|---|---|---|---|
| Current use | 54 | 10 | 31 | 95 |
| Quit/former use | 111 | 11 | 57 | 179 |
| Never used | 102 | 12 | 70 | 184 |
| Unknown | 1 | 0 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2023 to primary completion in Feb 2025, 19 months.
Results were first posted in Mar 2026, 1 year after primary completion.
Of 187 non-industry observational studies under HIV Infections, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's 19 months is below that.
Counting every sponsor, half of 201 studies reached it within 38 months; a quarter within 16 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AIDS Malignancy Consortium